AstraZeneca's Fasenra has been cleared for use by the NHS in England as an add-on treatment for the rare autoimmune disease ...

With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking to its projection to generate sales of more than 40 billion pounds sterling ...

UK-based big pharma GlaxoSmithKline (GSK) has released its Q2 2025 results, which highlight the varying successes of its current portfolio. While the company’s total sales in this period totalled £8bn ...

Investing.com -- GSK (LON: GSK) on Wednesday raised its full-year earnings guidance after posting a 35% rise in second-quarter profit, supported by continued strength in its HIV and oncology ...

GSK's Q2 earnings and revenues top forecasts, with Specialty Medicines and Vaccines driving growth and a raised 2025 outlook boosting shares.

The FDA has approved mepolizumab (Nucala), a biologic COPD treatment designed to reduce flare-ups. Learn how it works and who it might help.

NICE has recommend Teva’s latest asthma drug Cinqaero for regular NHS funding, after the manufacturer offered a discount.

GSK received three U.S. regulatory approvals during the quarter, including for the Penmenvy meningitis vaccine, the antibiotic Blujepa, and Nucala for COPD. A regulatory decision on depemokimab for ...

Britain's GSK and China's Jiangsu Hengrui Pharmaceuticals have agreed on a $500 million deal to develop up to a dozen new medicines, including a promising candidate for a chronic lung condition, the ...

GSK’s respiratory portfolio also showed strength, with Nucala receiving approval for COPD in May 2025, representing its fifth indication in the US. Pipeline Progress and R&D Investment ...

Further authorisations are expected this year for its Nucala COPD treatment, Blennrep multiple melanoma drug, and Depemokimab asthma treatment. Positive to me as well is that Q4 2024’s 1.15bn ...